安徽医学
安徽醫學
안휘의학
ANHUI MEDICAL JOURNAL
2015年
1期
30-33
,共4页
食管肿瘤%基因多态性%顺铂%紫杉醇%5-氟尿嘧啶
食管腫瘤%基因多態性%順鉑%紫杉醇%5-氟尿嘧啶
식관종류%기인다태성%순박%자삼순%5-불뇨밀정
Esophageal neoplasms%Genetic polymorphism%Cisplatin%Paclitaxel%5-fluorouracil
目的：初步探索外周血切除修复交叉互补基因1（ ERCC1）-C8092A位点多态性指导个体化治疗晚期食管癌患者的价值。方法120例晚期食管癌患者入组，随机选取40例为对照组予以顺铂联合紫杉醇方案化疗；80例干预组患者根据外周血ERCC1-C8092A位点基因型制定化疗方案，基因型为A／A或A／C型，采用顺铂联合紫杉醇方案化疗，基因型为C／C型，采用5-氟尿嘧啶联合紫杉醇方案化疗，每21天为1个周期，比较两组患者的近期有效率及不良反应的差异。结果对照组和干预组晚期食管癌患者近期有效率分别为31．6％和53．9％，差异有统计学意义（P＝0．024）；同样予以紫杉醇联合顺铂方案治疗下，对照组和干预组不良反应无统计学差异。结论根据外周血ERCC1-C8092A位点基因型制定化疗方案，可提高晚期食管癌患者的近期有效率，值得临床推广。
目的：初步探索外週血切除脩複交扠互補基因1（ ERCC1）-C8092A位點多態性指導箇體化治療晚期食管癌患者的價值。方法120例晚期食管癌患者入組，隨機選取40例為對照組予以順鉑聯閤紫杉醇方案化療；80例榦預組患者根據外週血ERCC1-C8092A位點基因型製定化療方案，基因型為A／A或A／C型，採用順鉑聯閤紫杉醇方案化療，基因型為C／C型，採用5-氟尿嘧啶聯閤紫杉醇方案化療，每21天為1箇週期，比較兩組患者的近期有效率及不良反應的差異。結果對照組和榦預組晚期食管癌患者近期有效率分彆為31．6％和53．9％，差異有統計學意義（P＝0．024）；同樣予以紫杉醇聯閤順鉑方案治療下，對照組和榦預組不良反應無統計學差異。結論根據外週血ERCC1-C8092A位點基因型製定化療方案，可提高晚期食管癌患者的近期有效率，值得臨床推廣。
목적：초보탐색외주혈절제수복교차호보기인1（ ERCC1）-C8092A위점다태성지도개체화치료만기식관암환자적개치。방법120례만기식관암환자입조，수궤선취40례위대조조여이순박연합자삼순방안화료；80례간예조환자근거외주혈ERCC1-C8092A위점기인형제정화료방안，기인형위A／A혹A／C형，채용순박연합자삼순방안화료，기인형위C／C형，채용5-불뇨밀정연합자삼순방안화료，매21천위1개주기，비교량조환자적근기유효솔급불량반응적차이。결과대조조화간예조만기식관암환자근기유효솔분별위31．6％화53．9％，차이유통계학의의（P＝0．024）；동양여이자삼순연합순박방안치료하，대조조화간예조불량반응무통계학차이。결론근거외주혈ERCC1-C8092A위점기인형제정화료방안，가제고만기식관암환자적근기유효솔，치득림상추엄。
Objective To investigate the values of peripheral blood excision repair cross complementation group 1 ( ERCCI )-C8092A genetic polymorphisms in predicting the prognosis of advanced esophageal cancer patients on individual.Methods One hundred and twenty patients with advanced esophageal cancer were enrolled in this study.The control group 40 patients were received cisplatin and paclita-xel .80 patients in the intervention group,A/A or A/C were received cisplatin and paclitaxel;C/C were received 5-fluorouracil and paclitax-el,every 21ds for 1 cycle.Then the response rate( RR) and adverse reactions were analyzed.Results The control group and the intervention group of patients with advanced esophageal cancer response rates were 31.6% and 53.9% (P=0.024) .The adverse reactions were the same.Conclusion According to peripheral blood ERCC1-C8092A genotype choosing chemotherapy can improve the patients with advanced esophageal carcinoma response rate,which is worthy of further promotion.
